

Global Molecular Diagnostics Point of Care Market: Focus on Application, Technology, Type, End User, Country Data (15 Countries), and Competitive Landscape – Analysis and Forecast, 2019-2029

<https://marketpublishers.com/r/GD5C565391D6EN.html>

Date: September 2019

Pages: 238

Price: US\$ 4,250.00 (Single User License)

ID: GD5C565391D6EN

Abstracts

Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities in the global molecular diagnostic point of care market?

What are the factors resulting in the emerging trends within the global molecular diagnostic point of care market?

How is each segment of the global molecular diagnostic point of care market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2029?

What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2029?

What are the key applications in the global molecular diagnostic point of care market? What are the major segments of these applications?

Who are the key manufacturers the global molecular diagnostic point of care products, and what are their contributions?

Global Molecular Diagnostic Point of Care Market Forecast, 2019-2029

The global molecular diagnostic point of care industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.14% during the forecast period, 2019-2029. The molecular diagnostic point of care market generated \$1,689.6 million revenue in 2018, in terms of value.

The molecular diagnostic point of care market growth has been primarily attributed to the major drivers in this market such as highly increasing global prevalence of infectious diseases and various types of cancer, growing demand for non-invasive diagnostics, increase in adoption of personalized medicines on a global level, and significant external funding for executing research and development exercises. The challenges include an uncertain reimbursement scenario, a lack of high-complexity testing centers, and high capital requirement hampering the global reach.

Expert Quote

“There is no doubt that near-patient molecular testing represents the future of diagnosing infectious diseases, especially those like influenza that are highly transmissible.”

Scope of the Market Intelligence on Global Molecular Diagnostic Point of Care Market

The molecular diagnostic point of care research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the diagnostic market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global molecular diagnostic point of care market.

Market Segmentation

The molecular diagnostic point of care market is segmented into infectious disease, oncology, prenatal testing and other applications, on the basis of application.

The molecular diagnostic point of care market is segmented into polymerase chain

reaction, isothermal nucleic acid amplification technology and other methods, on the basis of technology.

The molecular diagnostic point of care market is segmented into assays, systems and software, on the basis of type.

The molecular diagnostic point of care market is segmented into hospitals, clinics, diagnostic centers, and other end-users, on the basis of end-user.

The molecular diagnostic point of care market is segmented into North America, Europe, Asia-Pacific, Latin America and Rest-of-the-World, on the basis of geography.

Key Companies in the Molecular Diagnostic Point of Care Market

The key manufacturers who have been contributing significantly to the molecular diagnostic point of care market include Hologic, Inc., Abbott Laboratories, bioMerieux S.A., QIAGEN N.V., Quidel Corporation, Biocartis NV, Danaher Corporation, DiaSorin S.p.A., F. Hoffman-La Roche Ltd., Luminex Corporation, Mesa Biotech, QuantuMDx Group Ltd., Spartan Biosciences Inc., DxNA LLC, and Abacus Diagnostica Oy, among others.

Contents

EXECUTIVE SUMMARY

1 RESEARCH SCOPE AND METHODOLOGY

- 1.1 Scope of the Study
- 1.2 Research Methodology
- 1.3 Data Sources
- 1.4 Assumptions and Limitations
- 1.5 Data and Prediction Modeling

2 MARKET OVERVIEW

- 2.1 Market Available Molecular Diagnostics Point of Care Products
- 2.2 Molecular Diagnostics Point of Care in Clinical Diagnostics
- 2.3 Molecular Diagnostics Point of Care Technologies
- 2.4 Regulatory Framework
 - 2.4.1 Legal Requirements and Framework in U.S.
 - 2.4.2 Legal Requirements and Framework in Europe
 - 2.4.3 Legal Requirements and Framework in Asia-Pacific
 - 2.4.3.1 China
 - 2.4.3.2 Japan

3 MARKET DYNAMICS

- 3.1 Overview
- 3.2 Impact Analysis
- 3.3 Market Drivers
 - 3.3.1 Growing Demand for Non-Invasive Diagnosis
 - 3.3.2 Increasing Prevalence of Infectious Diseases and Various Types of Cancer on a Global Level
 - 3.3.3 Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
 - 3.3.4 Significant External Funding for Executing Research and Development Exercises
- 3.4 Market Restraint
 - 3.4.1 Uncertain Reimbursement Scenario
 - 3.4.2 Lack of High Complexity Testing Centers
 - 3.4.3 High Capital Requirement Hampering the Expansion of Global Reach

3.5 Market Opportunities

3.5.1 Massive Scope for Adoption of Molecular Diagnostics-Based Point of Care Products in Emerging Nations

3.5.2 Technological Advancements in Molecular Techniques and Diagnostic Tests

3.5.3 Hybridization of Technologies

4 COMPETITIVE LANDSCAPE

4.1 Key Strategies and Developments

4.1.1 Approvals

4.1.2 Synergistic Activities

4.1.3 Product Launches and Enhancements

4.1.4 Funding and Expansion Activities

4.1.5 Acquisitions

5 GLOBAL MOLECULAR DIAGNOSTICS POINT OF CARE MARKET (BY PRODUCT)

5.1 Overview

5.2 Assays

5.3 Systems

5.4 Software

6 GLOBAL MOLECULAR DIAGNOSTICS POINT OF CARE MARKET (BY APPLICATION)

6.1 Overview

6.2 Infectious Disease

6.2.1 Respiratory Infection

6.2.2 Hospital Acquired Infections (HAI)

6.2.3 Sexually Transmitted Infections (STIs)

6.2.4 Gastro-Intestinal Infections

6.3 Oncology

6.4 Pre-natal Testing

6.5 Others

7 GLOBAL MOLECULAR DIAGNOSTICS POINT OF CARE MARKET (BY TECHNOLOGY)

- 7.1 Overview
- 7.2 Polymerase Chain Reaction (PCR)
 - 7.2.1 Real-time PCR (q-PCR)
 - 7.2.2 Digital PCR (d-PCR)
- 7.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 7.4 Others

8 GLOBAL MOLECULAR DIAGNOSTICS POINT OF CARE MARKET (BY REGION)

- 8.1 Overview
- 8.2 North America
 - 8.2.1 U.S.
 - 8.2.2 Canada
- 8.3 Europe
 - 8.3.1 Germany
 - 8.3.2 U.K.
 - 8.3.3 France
 - 8.3.4 Italy
 - 8.3.5 Spain
 - 8.3.6 The Netherlands
 - 8.3.7 Rest-of-Europe
- 8.4 Asia-Pacific
 - 8.4.1 China
 - 8.4.2 Japan
 - 8.4.3 India
 - 8.4.4 Australia
 - 8.4.5 Singapore
 - 8.4.6 Rest-of-APAC
- 8.5 Latin America
 - 8.5.1 Brazil
 - 8.5.2 Mexico
 - 8.5.3 Rest-of-Latin America
- 8.6 Rest-of-the-World

9 GLOBAL MOLECULAR DIAGNOSTICS POINT OF CARE MARKET (BY END-USER)

- 9.1 Overview
- 9.2 Hospitals

9.3 Clinics

9.4 Diagnostic Centers

9.5 Other End-Users

10 INDUSTRY INSIGHTS

10.1 Market Share Analysis

10.2 Growth Share Analysis

11 COMPANY PROFILES

11.1 Abbott Laboratories

11.1.1 Company Overview

11.1.2 Role of Abbott Laboratories in the Global Molecular Diagnostics Point of Care Market

11.1.3 Financials

11.1.4 Key Insights about Financial Health of the Company

11.1.5 SWOT Analysis

11.2 Abacus Diagnostica Oy

11.2.1 Company Overview

11.2.2 Role of Abacus Diagnostica Oy in the Global Molecular Diagnostics Point of Care Market

11.2.3 SWOT Analysis

11.3 bioMérieux S.A.

11.3.1 Company Overview

11.3.2 Role of bioMérieux S.A. in the Global Molecular Diagnostics Point of Care Market

11.3.3 Financials

11.3.4 Key Insights about Financial Health of the Company

11.3.5 SWOT Analysis

11.4 Biocartis NV

11.4.1 Company Overview

11.4.2 Role of Biocartis NV in the Global Molecular Diagnostics Point of Care Market

11.4.3 Financials

11.4.4 Key Insights about Financial Health of the Company

11.4.5 SWOT Analysis

11.5 Danaher Corporation

11.5.1 Company Overview

11.5.2 Role of Danaher Corporation in the Global Molecular Diagnostics Point of Care Market

Market

11.5.3 Financials

11.5.4 Key Insights about Financial Health of the Company

11.5.5 SWOT Analysis

11.6 DiaSorin S.p.A

11.6.1 Company Overview

11.6.2 Role of DiaSorin S.p.A. in the Global Molecular Diagnostics Point of Care

Market

11.6.3 Financials

11.6.4 Key Insights about Financial Health of the Company

11.6.5 SWOT Analysis

11.7 DxNA LLC

11.7.1 Company Overview

11.7.2 Role of DxNA LLC in the Point of Care Global Molecular Diagnostics Point of

Care Market

11.7.3 SWOT Analysis

11.8 F. Hoffmann-La Roche Ltd

11.8.1 Company Overview

11.8.2 Role of F. Hoffmann-La Roche Ltd in the Global Molecular Diagnostics Point of

Care Market

11.8.3 Financials

11.8.4 Key Insights about Financial Health of the Company

11.8.5 SWOT Analysis

11.9 Luminex Corporation

11.9.1 Company Overview

11.9.2 Role of Luminex Corporation in the Global Molecular Diagnostics Point of Care

Market

11.9.3 Financials

11.9.4 Key Insights about Financial Health of the Company

11.9.5 SWOT Analysis

11.10 Hologic, Inc.

11.10.1 Company Overview

11.10.2 Role of Hologic, Inc. in the Molecular Diagnostic Point of Care Market

11.10.3 Financials

11.10.4 Key Insights about Financial Health of the Company

11.10.5 SWOT Analysis

11.11 Mesa Biotech

11.11.1 Company Overview

11.11.2 Role of Mesa Biotech in the Molecular Diagnostics Point of Care Market

11.11.3 SWOT Analysis

11.12 Spartan Biosciences Inc.

11.12.1 Company Overview

11.12.2 Role of Spartan Biosciences Inc. in the Molecular Diagnostics Point of Care Market

11.12.3 SWOT Analysis

11.13 QuantuMDx Group Ltd.

11.13.1 Company Overview

11.13.2 Role of QuantuMDx Group Ltd. in the Global Molecular Diagnostics Point of Care Market

11.13.3 SWOT Analysis

11.14 Quidel Corporation

11.14.1 Company Overview

11.14.2 Role of Quidel Corporation the Global Molecular Diagnostics Point of Care Market

11.14.3 Financials

11.14.4 Key Insights about Financial Health of the Company

11.14.5 SWOT Analysis

11.15 QIAGEN N.V.

11.15.1 Company Overview

11.15.2 Role of QIAGEN N.V. in the Global Molecular Diagnostics Point of Care Market

11.15.3 Financials

11.15.4 Key Insights about Financial Health of the Company

11.15.5 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 2.1: Market Available Molecular Diagnostics Point of Care Products

Table 2.2: Classification rules of IVDs under the IVDR

Table 2.3: Registration Criteria for IVD Medical Devices as per the CFDA

Table 3.1: Impact Analysis of Market Drivers

Table 3.2: Impact Analysis of Market Restraints

Table 6.1: Global Estimates of New Cases of Curable STIs in 2016

List Of Figures

LIST OF FIGURES

Figure 1: Impact of Market Drivers and Market Restraints on the Global Molecular Diagnostics Point of Care Market

Figure 2: Global Molecular Diagnostics Point of Care Market Snapshot, 2018 and 2029

Figure 3: Dominating Segments of the Global Molecular Diagnostics Point of Care Market, 2019 and 2029

Figure 4: Key Strategies Incorporated by Stakeholders of Molecular Diagnostics Point of Care Market, to Sustain the Competition (from January 2016 to August 2019)

Figure 5: Global Molecular Diagnostics Point of Care Market Point of Care (by Product), 2018 and 2029

Figure 6: Global Molecular Diagnostics Point of Care Market (by Technology), 2018 and 2029

Figure 7: Global Molecular Diagnostics Point of Care Market (by End-User), 2018 and 2029

Figure 8: Global Molecular Diagnostics Point of Care Market (by Region) 2018 and 2029

Figure 1.1: Global Molecular Diagnostics Point-of-Care Market Segmentation

Figure 1.2: Global Molecular Diagnostics Point of Care Market Research Methodology

Figure 1.3: Primary Research

Figure 1.4: Secondary Research

Figure 1.5: Data Triangulation

Figure 1.6: Bottom-Up Approach (Segment-Wise Analysis)

Figure 1.7: Top-Down Approach (Segment-Wise Analysis)

Figure 1.8: Assumptions and Limitations

Figure 1.9: Considered Factors for Data Prediction and Modeling

Figure 2.1: Characteristics of a Commercially Available Molecular Diagnostics Point of Care Products

Figure 2.2: Components Considered for Clinical Evidence as per the IVDR

Figure 3.1: Number of Deaths due to top 18 Infectious Diseases on a Global Scale, 2015

Figure 3.2: Number of Deaths due to Different Forms of Cancer, Million Units, 2018,

Figure 4.1: Share of Key Developments and Strategies, January 2016 – August 2019

Figure 4.2: Approvals Share (by Company), January 2016 – August 2019

Figure 4.3: Synergistic Activities Share (by Company), January 2016 – August 2019

Figure 4.4: Product Launches and Enhancements Share (by Company), January 2016 – August 2019

- Figure 4.5: Funding Share (by Company), January 2016 – August 2019
- Figure 4.6: Acquisitions Share (by Company), January 2016 – August 2019
- Figure 5.1: Global Molecular Diagnostics Point of Care Market (by Product)
- Figure 5.2: Global Molecular Diagnostics Point of Care Market (by Product), 2018-2029
- Figure 5.3: General Workflow of a Molecular Diagnostics Point of Care Kit
- Figure 5.4: Global Molecular Diagnostics Point of Care Market (Assays), 2018-2029
- Figure 5.5: Global Molecular Diagnostics Point of Care Market (by Systems), 2018-2029
- Figure 5.7: Aspects of Software Development
- Figure 5.8: Global Molecular Diagnostics Point of Care Market (by Software), 2018-2029
- Figure 6.1: Global Molecular Diagnostics Point of Care Market (by Application), 2018-2029
- Figure 6.2: Global Molecular Diagnostics Point of Care Market (by Infectious Disease), 2018-2029
- Figure 6.3: Global Molecular Diagnostics Point of Care Market (by Infectious Disease Type), 2018-2020
- Figure 6.4: Global Molecular Diagnostics Point of Care Market (by Respiratory Infections), 2018-2029
- Figure 6.5: Global Molecular Diagnostics Point of Care Market (by Hospital Acquired Infections), 2018-2029
- Figure 6.6: Global Molecular Diagnostics Point of Care Market (by Sexually Transmitted Infections), 2018-2029
- Figure 6.7: Global Molecular Diagnostics Point of Care Market (by Gastro-Intestinal Infections), 2018-2029
- Figure 6.8: Global Molecular Diagnostics Point of Care Market (by Oncology), 2018-2029
- Figure 6.9: Global Molecular Diagnostics Point of Care Market (by Pre-natal Testing), 2018-2029
- Figure 6.10: Global Molecular Diagnostics Point of Care Market (by Other Applications), 2018-2029
- Figure 7.1: Global Molecular Diagnostics Point of Care Market (by Technology), 2018-2029
- Figure 7.2: Global Molecular Diagnostics Point of Care Market (by PCR), 2018-2029
- Figure 7.3: Global Molecular Diagnostics Point of Care Market (by q-PCR), 2018-2029
- Figure 7.4: Global Molecular Diagnostics Point of Care Market (by d-PCR), 2020-2029
- Figure 7.5: Global Molecular Diagnostics Point of Care Market (by INAAT), 2018-2029
- Figure 7.6: Global Molecular Diagnostics Point of Care Market (by Other Technologies), 2018-2029
- Figure 8.1: Global Molecular Diagnostics Point of Care Market (by Region), 2018 and

2029

Figure 8.2: Global Molecular Diagnostics Point of Care Market Point of Care (by Region), 2018-2029

Figure 8.3: Global Molecular Diagnostics Point of Care Market Share (by Region), 2018

Figure 8.4: Global Molecular Diagnostics Point of Care Market Share (by Region), 2029

Figure 8.5: North America Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.6: North America Molecular Diagnostics Point of Care Market (by Country), 2018-2029

Figure 8.7: North America: Market Dynamics

Figure 8.8: The U.S. Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.9: Canada Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.10: Overview of Reimbursement Policies in Europe (Focus on Companion Diagnostics as well)

Figure 8.11: Europe Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.12: Europe: Market Dynamics

Figure 8.13: Europe Molecular Diagnostics Point of Care Market (by Country), 2018-2029

Figure 8.14: Germany Point of Care Molecular Diagnostics Market, 2018-2029

Figure 8.15: U.K. Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.16: France Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.17: Italy Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.18: Spain Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.19: The Netherlands Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.20: Rest-of-Europe Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.21: Asia-Pacific Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.22: APAC: Market Dynamics

Figure 8.23: APAC Global Molecular Diagnostics Point of Care Market (by Country), 2018-2029

Figure 8.24: China Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.25: Japan Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.26: India Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.27: Australia Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.28: Singapore Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.29: RoAPAC Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.30: Latin America Molecular Diagnostics Point of Care Market, 2018-2029

Figure 8.31: Latin America: Market Dynamics

Figure 8.32: Latin America Molecular Diagnostics Point of Care Market (by Country), 2018-2029

Figure 8.33: Brazil Molecular Diagnostics Point of Care Market 2018-2029

- Figure 8.34: Mexico Molecular Diagnostics Point of Care Market, 2018-2029
- Figure 8.35: Rest-of-Latin America Molecular Diagnostics Point of Care Market, 2018-2029
- Figure 8.36: RoW Molecular Diagnostics Point of Care Market, 2018-2029
- Figure 9.1: Global Molecular Diagnostics Point of Care Market (by End-User)
- Figure 9.2: Global Molecular Diagnostics Point of Care Market (by End User), 2018-2029
- Figure 9.3: Global Molecular Diagnostics Point of Care Market (by Hospitals), 2018-2029
- Figure 9.4: Global Molecular Diagnostics Point of Care Market (by Clinics), 2018-2029
- Figure 9.5: Global Molecular Diagnostics Point of Care Market (Diagnostic Centers), 2018-2029
- Figure 9.6: Global Molecular Diagnostics Point of Care Market (by Other End-Users), 2018-2029
- Figure 10.1: Market Share Analysis for the Global Molecular Diagnostics Point of Care Market, 2018
- Figure 10.2: Growth Share Matrix for Molecular Diagnostics Point of Care Market (by Company), 2018
- Figure 11.1: Total Number of Companies Profiled
- Figure 11.2: Abbott Laboratories: Overall Product Portfolio
- Figure 11.3: Abbott Laboratories: Overall Financials, 2016-2018
- Figure 11.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
- Figure 11.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
- Figure 11.6: Abbott Laboratories: Revenue (by Region), 2016-2018
- Figure 11.7: Abbott Laboratories: R&D Expenditure, 2016-2018
- Figure 11.8: Abbott Laboratories: SWOT Analysis
- Figure 11.9: Abacus Diagnostica Oy.: Overall Product Portfolio (Available from FY2019)
- Figure 11.10: Abacus Diagnostica Oy: SWOT Analysis
- Figure 11.11: bioMérieux S.A.: Overall Product Portfolio
- Figure 11.12: bioMérieux S.A.: Overall Financials, 2016-2018
- Figure 11.13: bioMérieux S.A.: Revenue (by Segment), 2016-2018
- Figure 11.14: bioMérieux S.A.: Revenue (by Region), 2016-2018
- Figure 11.15: bioMérieux S.A.: R&D Expenditure, 2016-2018
- Figure 11.16: bioMérieux S.A.: SWOT Analysis
- Figure 11.17: Biocartis NV: Overall Product Portfolio
- Figure 11.18: Biocartis NV: Overall Financials, 2016-2018
- Figure 11.19: Biocartis NV: R&D Expenditure, 2016-2018
- Figure 11.20: Biocartis NV: SWOT Analysis
- Figure 11.21: Danaher Corporation: Molecular Diagnostics Point of Care Product

Portfolio

- Figure 11.22: Danaher Corporation: Overall Financials, 2016-2018
- Figure 11.23: Danaher Corporation: Revenue (by Business Segment), 2016-2018
- Figure 11.24: Danaher Corporation: Revenue (by Region), 2016-2018
- Figure 11.25: Danaher Corporation: R&D Expenditure, 2016-2018
- Figure 11.26: Danaher Corporation: SWOT Analysis
- Figure 11.27: DiaSorin S.p.A.: Overall Financials, 2016-2018
- Figure 11.28: DiaSorin S.p.A.: Revenue (by Segment), 2016-2018
- Figure 11.29: DiaSorin S.p.A.: By Region, 2016-2018
- Figure 11.30: DiaSorin S.p.A: R&D Expenditure, 2016-2018
- Figure 11.31: DiaSorin S.p.A: SWOT Analysis
- Figure 11.32: DxNA LLC.: Overall Product Portfolio (Available from FY2019)
- Figure 11.33: DxNA LLC Group Ltd.: SWOT Analysis
- Figure 11.34: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
- Figure 11.35: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
- Figure 11.36: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
- Figure 11.37: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
- Figure 11.38: F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
- Figure 11.39: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
- Figure 11.40: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
- Figure 11.41: F. Hoffmann-La Roche Ltd: SWOT Analysis
- Figure 11.42: Luminex Corporation: Overall Product Portfolio
- Figure 11.43: Luminex Corporation: Overall Financials, 2016-2018
- Figure 11.44: Luminex Corporation: Revenue (by Segment), 2016-2018
- Figure 11.45: Luminex Corporation: Revenue (by Region), 2016-2018
- Figure 11.46: Luminex Corporation: R&D Expenditure, 2016-2018
- Figure 11.47: Luminex Corporation: SWOT Analysis
- Figure 11.48: Hologic, Inc.: Overall Product Portfolio
- Figure 11.49: Hologic, Inc.: Overall Financials, 2016-2018
- Figure 11.50: Hologic, Inc.: Revenue (by Segment), 2016-2018
- Figure 11.51: Hologic, Inc.: Revenue (by Region), 2016-2018
- Figure 11.52: Hologic, Inc.: R&D Expenditure, 2016-2018
- Figure 11.53: Hologic, Inc.: SWOT Analysis
- Figure 11.54: Mesa Biotech: Overall Product Portfolio (Available from FY2019)
- Figure 11.55: Mesa Biotech: SWOT Analysis
- Figure 11.56: Spartan Biosciences Inc.: Overall Product Portfolio (Available from FY2019)
- Figure 11.57: Spartan Biosciences, Inc.: SWOT Analysis
- Figure 11.58: QuantuMDx Group Ltd.: Overall Product Portfolio (Available from FY2019)

- Figure 11.59: QuantuMDx Group Ltd.: SWOT Analysis
- Figure 11.60: Quidel Corporation Ltd.: Overall Product Portfolio (Available from FY2019)
- Figure 11.61: Quidel Corporation: Overall Financials, 2016-2018
- Figure 11.62: Quidel Corporation: Revenue (by Segment), 2016-2018
- Figure 11.63: Quidel Corporation: Revenue (by Region), 2016-2018
- Figure 11.64: Quidel Corporation: R&D Expenditure, 2016-2018
- Figure 11.65: Quidel Corporation: SWOT Analysis
- Figure 11.66: QIAGEN N.V.: Overall Product Portfolio
- Figure 11.67: QIAGEN N.V.: Overall Financials, 2016-2018
- Figure 11.68: QIAGEN N.V.: Revenue (by Segment), 2016-2018
- Figure 11.69: QIAGEN N.V.: Revenue (by Region), 2016-2018
- Figure 11.70: QIAGEN N.V.: R&D Expenditure, 2016-2018
- Figure 11.71: QIAGEN N.V.: SWOT Analysis

I would like to order

Product name: Global Molecular Diagnostics Point of Care Market: Focus on Application, Technology, Type, End User, Country Data (15 Countries), and Competitive Landscape – Analysis and Forecast, 2019-2029

Product link: <https://marketpublishers.com/r/GD5C565391D6EN.html>

Price: US\$ 4,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD5C565391D6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970